Harbour Antibodies BV was established in 2006 to use transgenic mouse technology developed in the laboratory of Professor Frank Grosveld at Erasmus MC (Rotterdam, the Netherlands) for engineering mice to produce high affinity human antibodies. The company has developed two types of human immunoglobulin gene transgenic mice: mice that generate “conventional” tetrameric antibodies comprising two heavy and two light immunoglobulin chains (H2L2); and alternatively, mice that generate heavy chain only antibodies comprising two immunoglobulin heavy chains with no light chains (HCAbs). Availability of HCAbs facilitates the generation of soluble human VH domains (human heavy chain variable region domains), the minimal immunoglobulin recognition unit, and thus the construction of novel multi-functional molecules comprising either two (or more) VH domains or one VH domain coupled to other molecules. Both Harbour transgenic mouse lines are now available to licensing partners.
HQCambridge, US
Size (employees)2 (est)
Harbour Antibodies was founded in 2006 and is headquartered in Cambridge, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Harbour Antibodies

Robert Kamen

Robert Kamen

Frank Grosveld

Frank Grosveld

CSO and Founder
Show more

Harbour Antibodies Office Locations

Harbour Antibodies has an office in Cambridge
Show all (1)
Report incorrect company information

Harbour Antibodies Financials and Metrics

Summary Metrics

Founding Date


Harbour Antibodies total Funding

$3.2 m

Harbour Antibodies latest funding size

$3.20 m

Time since last funding

5 years ago

Harbour Antibodies investors

Harbour Antibodies's latest funding round in July 2013 was reported to be $3.2 m. In total, Harbour Antibodies has raised $3.2 m
Show all financial metrics
Report incorrect company information

Harbour Antibodies Company Life and Culture

Report incorrect company information